Sign In
Buy GRFS
$7.18
-0.100 (-1.37%)
At Close: Jun 23, 2026
Grifols Class B: Buy The Recovery In The U.S. Plasma Business
08:00am, Wednesday, 11'th Nov 2020
Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging.
Grifols Looks Enticing After Big Sell-Off In Spain
01:07am, Friday, 30'th Oct 2020
The Spanish market has gotten crushed with an uptick in COVID-19 deaths. Grifols stock is about where it was when I visited headquarters three years ago.
CSL Limited: A Twindemic Can Unravel A Pricey Premium
11:43am, Sunday, 13'th Sep 2020
The pandemic-related lockdowns have dried up CSL’s plasma supplies, though a possible flu outbreak can accelerate the influenza vaccine sales and offset the impact of a slowdown in plasma-derived pr
Tracking George Soros's Portfolio - Q2 2020 Update
01:21pm, Friday, 21'st Aug 2020
Soros' 13F portfolio value increased from $1.98B to $4.48B this quarter. The number of positions increased from 118 to 141.
ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injecti
Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
10:04pm, Wednesday, 05'th Aug 2020
The results provide more justification for the FDA to grant the substance emergency use authorization.
Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript
06:01am, Wednesday, 05'th Aug 2020
It is now my pleasure to introduce our first speaker Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. As a reminder, during today's call we may make forwar
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials
02:41pm, Tuesday, 28'th Jul 2020
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's he
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, the prestigious peer-reviewed scientific journal, today has published the results of Grifols' AMBAR study. This clinical trial was d
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products
12:00pm, Thursday, 23'rd Jul 2020
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has acquired
Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety
10:51am, Wednesday, 22'nd Jul 2020
US and global pharma companies that are working on credible COVID-19 treatments are up massively YTD, often more than 100% and far surpassing performance of general pharma indices.
Grifols Buys Plasma Assets From Green Cross For $460M To Boost Canada Business
11:39am, Monday, 20'th Jul 2020
Grifols SA (GRFS) announced on Monday that it has acquired plasma assets in North America and a plasma facility in Montreal from South Korea’s Green Cross Pharma for a total of $460 million.Shares r
Spanish pharma Grifols buys plasma assets from Green Cross for $460 million
06:55am, Monday, 20'th Jul 2020
Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea's Green Cross for $460 million. Grifols will buy a plasma fractionation plant in
\\- Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.
Spanish pharma Grifols buys plasma assets from Green Cross for $460 mln
06:36am, Monday, 20'th Jul 2020
Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea's Green Cross for $460 million. Grifols will buy a plasma fractionation plant in
